Literature DB >> 11698249

ARCD-1, an apobec-1-related cytidine deaminase, exerts a dominant negative effect on C to U RNA editing.

S Anant1, D Mukhopadhyay, V Sankaranand, S Kennedy, J O Henderson, N O Davidson.   

Abstract

Mammalian apolipoprotein B (apoB) C to U RNA editing is catalyzed by a multicomponent holoenzyme containing a single catalytic subunit, apobec-1. We have characterized an apobec-1 homologue, ARCD-1, located on chromosome 6p21.1, and determined its role in apoB mRNA editing. ARCD-1 mRNA is ubiquitously expressed; phylogenetic analysis reveals it to be a distant member of the RNA editing family. Recombinant ARCD-1 demonstrates cytidine deaminase and apoB RNA binding activity but does not catalyze C to U RNA editing, either in vitro or in vivo. Although not competent itself to mediate deamination of apoB mRNA, ARCD-1 inhibits apobec-1-mediated C to U RNA editing. ARCD-1 interacts and heterodimerizes with both apobec-1 and apobec-1 complementation factor (ACF) and localizes to both the nucleus and cytoplasm of transfected cells. Together, the data suggest that ARCD-1 is a novel cytidine deaminase that interacts with apobec-1 and ACF to inhibit apoB mRNA editing, possibly through interaction with other protein components of the apoB RNA editing holoenzyme.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698249     DOI: 10.1152/ajpcell.2001.281.6.C1904

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  13 in total

Review 1.  The challenge of target sequence specificity in C-->U RNA editing.

Authors:  Nicholas O Davidson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

2.  Injury-dependent Müller glia and ganglion cell reprogramming during tissue regeneration requires Apobec2a and Apobec2b.

Authors:  Curtis Powell; Fairouz Elsaeidi; Daniel Goldman
Journal:  J Neurosci       Date:  2012-01-18       Impact factor: 6.167

Review 3.  APOBEC family proteins: novel antiviral innate immunity.

Authors:  Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

4.  Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished body mass, and myopathy.

Authors:  Yusuke Sato; Hans Christian Probst; Ryuichi Tatsumi; Yoshihide Ikeuchi; Michael S Neuberger; Cristina Rada
Journal:  J Biol Chem       Date:  2009-12-17       Impact factor: 5.157

5.  Mice deficient in APOBEC2 and APOBEC3.

Authors:  Marie C Mikl; Ian N Watt; Mason Lu; Wolf Reik; Sarah L Davies; Michael S Neuberger; Cristina Rada
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

6.  APOBEC2, a selective inhibitor of TGFβ signaling, regulates left-right axis specification during early embryogenesis.

Authors:  Alin Vonica; Alessandro Rosa; Brigitte L Arduini; Ali H Brivanlou
Journal:  Dev Biol       Date:  2010-09-27       Impact factor: 3.582

7.  Lack of Apobec2-related proteins causes a dystrophic muscle phenotype in zebrafish embryos.

Authors:  Christelle Etard; Urmas Roostalu; Uwe Strähle
Journal:  J Cell Biol       Date:  2010-05-03       Impact factor: 10.539

8.  Biochemical and molecular characterization of two cytidine deaminases in the nematode Caenorhabditis elegans.

Authors:  Fiona J Thompson; Collette Britton; Isla Wheatley; Kirsty Maitland; Glenda Walker; Shrikant Anant; Nicholas O Davidson; Eileen Devaney
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

9.  Zinc-binding domain-dependent, deaminase-independent actions of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 2 (Apobec2), mediate its effect on zebrafish retina regeneration.

Authors:  Curtis Powell; Eli Cornblath; Daniel Goldman
Journal:  J Biol Chem       Date:  2014-09-04       Impact factor: 5.157

10.  Analysis of DNA methylation reveals a partial reprogramming of the Müller glia genome during retina regeneration.

Authors:  Curtis Powell; Ana R Grant; Eli Cornblath; Daniel Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.